Avalo Therapeutics, Inc. Common Stock

AVTX XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

980M

Short interest (Jun 30)

23.4%

Net Short (Jul 27 ): 0.1%

Borrow Fee

0.58%

↑ 7.0%

Available Shares

↑ 255.8%

Price Chart

Company Overview

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001534120

Asset Type: CS

Market Data

Market Cap: $975,531,117

Employees: 33

Status: Active

Short Interest

Current Borrow Fee 0.58%

Range: 0.58% - 0.58%

Available Shares 4M

Range: 80K - 3.9M

Recent Changes

Fee Change: ↓ 0.2%

Available Change: ↑ 20.6%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime